Session

Endoscopic treatment of Barrett's and oesophageal neoplasia

FEASIBILITY OF THE CYTOSPONGE COUPLED WITH TISSUE BIOMARKERS IN EARLY DIAGNOSIS OF OESOPHAGEAL SQUAMOUS CELL CARCINOMA AND SURVEILLANCE OF HIGH-RISK INDIVIDUALS: PRELIMINARY RESULTS FROM THE EDEN STUDY
FEASIBILITY OF THE CYTOSPONGE COUPLED WITH TISSUE BIOMARKERS IN EARLY DIAGNOSIS OF OESOPHAGEAL SQUAMOUS CELL CARCINOMA AND SURVEILLANCE OF HIGH-RISK INDIVIDUALS: PRELIMINARY RESULTS FROM THE EDEN STUDY

OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) FOR BARRETT’S NEOPLASIA – A SINGLE CENTRE PROSPECTIVE STUDY
OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) FOR BARRETT’S NEOPLASIA – A SINGLE CENTRE PROSPECTIVE STUDY

CLINICAL STRATIFICATION FOR ENDOSCOPIC SUBMUCOSAL DISSECTION VERSUS ENDOSCOPIC MUCOSAL RESECTION FOR BARRETT'S ASSOCIATED NEOPLASIA: LONG-TERM FOLLOW-UP
CLINICAL STRATIFICATION FOR ENDOSCOPIC SUBMUCOSAL DISSECTION VERSUS ENDOSCOPIC MUCOSAL RESECTION FOR BARRETT'S ASSOCIATED NEOPLASIA: LONG-TERM FOLLOW-UP

HIGH RISK FOR UNRELATED MORTALITY AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA IN A NATIONWIDE COHORT OF 1154 PATIENTS
HIGH RISK FOR UNRELATED MORTALITY AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA IN A NATIONWIDE COHORT OF 1154 PATIENTS

RANDOM BIOPSIES FROM THE GASTRO-ESOPHAGEAL JUNCTION AFTER COMPLETE ERADICATION OF BARRETT’S ESOPHAGUS: UTILE OR FUTILE?
RANDOM BIOPSIES FROM THE GASTRO-ESOPHAGEAL JUNCTION AFTER COMPLETE ERADICATION OF BARRETT’S ESOPHAGUS: UTILE OR FUTILE?

RANDOM BIOPSIES FROM THE GASTRO-ESOPHAGEAL JUNCTION AFTER COMPLETE ERADICATION OF BARRETT’S ESOPHAGUS: UTILE OR FUTILE?
RANDOM BIOPSIES FROM THE GASTRO-ESOPHAGEAL JUNCTION AFTER COMPLETE ERADICATION OF BARRETT’S ESOPHAGUS: UTILE OR FUTILE?

Endoscopic treatment of Barrett's and oesophageal neoplasia  et al.

HIGH RISK FOR UNRELATED MORTALITY AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA IN A NATIONWIDE COHORT OF 1154 PATIENTS
HIGH RISK FOR UNRELATED MORTALITY AFTER SUCCESSFUL ENDOSCOPIC ERADICATION THERAPY FOR BARRETT’S NEOPLASIA IN A NATIONWIDE COHORT OF 1154 PATIENTS

Endoscopic treatment of Barrett's and oesophageal neoplasia  et al.

CLINICAL STRATIFICATION FOR ENDOSCOPIC SUBMUCOSAL DISSECTION VERSUS ENDOSCOPIC MUCOSAL RESECTION FOR BARRETT'S ASSOCIATED NEOPLASIA: LONG-TERM FOLLOW-UP
CLINICAL STRATIFICATION FOR ENDOSCOPIC SUBMUCOSAL DISSECTION VERSUS ENDOSCOPIC MUCOSAL RESECTION FOR BARRETT'S ASSOCIATED NEOPLASIA: LONG-TERM FOLLOW-UP

Endoscopic treatment of Barrett's and oesophageal neoplasia  et al.

OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) FOR BARRETT’S NEOPLASIA – A SINGLE CENTRE PROSPECTIVE STUDY
OUTCOMES OF ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) FOR BARRETT’S NEOPLASIA – A SINGLE CENTRE PROSPECTIVE STUDY

Endoscopic treatment of Barrett's and oesophageal neoplasia  et al.

FEASIBILITY OF THE CYTOSPONGE COUPLED WITH TISSUE BIOMARKERS IN EARLY DIAGNOSIS OF OESOPHAGEAL SQUAMOUS CELL CARCINOMA AND SURVEILLANCE OF HIGH-RISK INDIVIDUALS: PRELIMINARY RESULTS FROM THE EDEN STUDY
FEASIBILITY OF THE CYTOSPONGE COUPLED WITH TISSUE BIOMARKERS IN EARLY DIAGNOSIS OF OESOPHAGEAL SQUAMOUS CELL CARCINOMA AND SURVEILLANCE OF HIGH-RISK INDIVIDUALS: PRELIMINARY RESULTS FROM THE EDEN STUDY

Endoscopic treatment of Barrett's and oesophageal neoplasia  et al.

Item 1 - 10 / 10
1